CompletedEUCTR 2005-003006-29
A Randomized, Double-blind, Placebo-controlled, Parallel-group Trial of the Anxiolytic Efficacy of Pregabalin and Alprazolam IR in Subjects with Anxiety prior to Dental Procedure
This historical record does not confirm current site availability.
Historical research recordGermany + United Kingdom
Understand this study
What did researchers investigate?
This EU register entry describes an interventional medicine trial, designed to assign participants a study treatment. The protocol sets out the treatment, eligibility criteria and assessments. Check the source details below for country statuses and any transfer to CTIS.
Who was this study for?
This study was for people with anxiety. Other eligibility criteria applied.
- Listed locations
- Germany · United Kingdom
- Study phase
- Phase 2Usually explores whether the intervention may work, while continuing to monitor safety.
Study information
Study start dateNot clearly listed
- Recruitment status
- Completed
- Enrollment listed in the registry
- 90
- Sponsor
- Pfizer Limited
- Sponsor type
- Unknown or unclear
- Study type
- Drug
- Intervention type
- Medication / drug
- Study phase
- Phase 2Usually explores whether the intervention may work, while continuing to monitor safety.
- Locations
- United Kingdom, Germany
- Age range
- Not clearly listed
- Official registry ID
- EUCTR 2005-003006-29
- Official title
Show the full official title
A Randomized, Double-blind, Placebo-controlled, Parallel-group Trial of the Anxiolytic Efficacy of Pregabalin and Alprazolam IR in Subjects with Anxiety prior to Dental Procedure
Get this study by email
Recruitment & locations
CompletedGermany · United Kingdom
Registry details
Historical country statuses
- Germany — Completed
- United Kingdom — Completed
Questions about this study
Who is behind this study?
The study sponsor is Pfizer Limited.
Who was this study for?
This study was for people with anxiety. Other eligibility criteria applied.
Want to explore more studies?
Explore studiesRelated studies
A Comparison of Duloxetine Hydrochloride, Venlafaxine Extended Release, and Placebo in the Treatment of Generalized Anxiety Disorder
A Dose-Response Safety Study of ENX-102 in Patients With GAD